Menopause Treatment: A Complete Guide to Your Options

If you are navigating the menopausal transition, you have likely heard conflicting messages about menopause treatment. One clinic pushes hormone therapy. A friend swears by black cohosh. Your social media feed advertises “bioidentical” creams that cost a fortune. Sorting fact from marketing is exhausting. This guide cuts through the noise. It covers every major category of menopause treatment — hormonal, non-hormonal pharmaceutical, lifestyle, dietary, and mind-body — with the evidence for each, the trade-offs, and exactly where the research stands in 2026. You will walk away knowing what works, what does not, and how to build a plan that fits your body and your values.

What You Are Actually Treating

Menopause is not a disease. It is a biological event — the permanent end of menstrual cycles, confirmed after twelve consecutive months without a period. The median age in the United States is 51, but perimenopause can begin four to eight years earlier. During that window, estrogen and progesterone levels fluctuate and then fall. The result is a constellation of symptoms that vary wildly between women.

Approximately 80% of women experience hot flashes (vasomotor symptoms). For about one in three, those flashes are severe enough to disrupt daily life and sleep. Beyond heat, common complaints include vaginal dryness, urinary urgency, brain fog, joint pain, mood changes, and accelerated bone density loss. The severity and mix of symptoms differ per person, which is why cookie-cutter menopause treatment plans fail. Your neighbor’s magic bullet is not your magic bullet.

Here is a number that matters: during the first five years after the final menstrual period, women can lose up to 20% of their bone density. That is a bigger drop than in any other five-year window in adulthood, including old age. The consequences — fractures, height loss, immobility — are often framed as inevitable parts of aging. They are not. Early intervention changes the trajectory. A 2025 precision pharmacology review in Frontiers in Reproductive Health noted that tailoring treatment to symptom profile, age at menopause onset, and cardiovascular risk factors produces substantially better long-term outcomes than a one-size-fits-all approach (Frontiers, 2025).

Hormone Therapy: The Gold Standard in Menopause Treatment That Got Buried

Menopausal hormone therapy (MHT) — often called HRT — remains the most effective menopause treatment for moderate-to-severe vasomotor symptoms. It also treats genitourinary syndrome of menopause (GSM) and prevents postmenopausal osteoporosis. The data are not subtle. A 2025 comprehensive review in the International Journal of Molecular Sciences reaffirmed that MHT cuts hot flash frequency by 75—85% in most women, a magnitude no other single intervention matches (IJMS, 2025).

How the WHI Study Broke Everything

In 2002, the Women’s Health Initiative published results linking combined estrogen-progestin therapy to increased breast cancer and cardiovascular risk. The media coverage was apocalyptic. Prescriptions plummeted by 80% almost overnight. Generations of doctors trained to avoid HRT like a live wire. The problem? The WHI studied women with an average age of 63 — a full decade past the typical menopause age — using a specific pill formulation (conjugated equine estrogen with medroxyprogesterone acetate) that is no longer standard. Later re-analyses showed that women who started MHT within ten years of menopause onset actually had lower all-cause mortality and reduced coronary artery calcium scores.

The damage persists. A 2024 survey in the UK found that only 12% of eligible women use MHT. France and Nordic countries, where prescription patterns never cratered the same way, see usage rates closer to 30—50%. The gap is not biology. It is legacy fear from a single flawed study.

What the FDA Expert Panel Said in July 2025

On July 17, 2025, the FDA convened an expert panel to formally re-examine the risks and benefits of hormone therapy for menopause. The panel focused specifically on the breast cancer, uterine cancer, and cardiovascular risk signals versus the benefits for bone, genitourinary, and cardiovascular health. The consensus was clear: the old “black box” warnings overshoot the evidence for women under 60 or within ten years of menopause onset. The panel signaled that updated labeling should reflect age-stratified risk. The Society for Women’s Health Research submitted comments urging the FDA to modernize its framework and remove blanket warnings that deter eligible women from treatment (SWHR, 2025). This is the most significant regulatory shift in menopause pharmacotherapy in over two decades.

Trade-Offs You Need to Know

• Estrogen alone (for women without a uterus): lowest risk profile. Linked to reduced breast cancer incidence in long-term WHI follow-up. No need for progestin.
• Estrogen plus progestin (for women with a uterus): progestin protects the endometrium but slightly raises breast cancer risk beyond estrogen alone. Transdermal estradiol with micronized progesterone is the modern safer alternative.
• Timing is everything. Starting MHT after age 60 or more than ten years past menopause onset flips the risk-benefit calculus: cardiovascular protection becomes cardiovascular risk. The “window of opportunity” is real.
• Bioidentical hormones. Custom-compounded “bioidentical” creams are heavily marketed. The Endocrine Society and The Menopause Society both advise against them — no FDA oversight, no standardized dosing, and zero long-term safety data. FDA-approved bioidentical products (17—estradiol patches, gels, micronized progesterone capsules) are the evidence-based alternative.

My take: for symptomatic women under 60 who are healthy and within ten years of menopause, MHT is underused to the point of malpractice avoidance. The pendulum swung too far in 2002 and still has not settled in the right place. The FDA panel is a step toward correction, but clinical practice lags years behind regulatory signals.

Non-Hormonal Prescription Drugs: The New Frontier

Not everyone can or wants to take hormones. Women with a history of breast cancer, blood clots, or certain cardiovascular conditions have limited options. That is where the newer non-hormonal drugs matter.

Fezolinetant (Veozah)

Approved by the FDA in May 2023, fezolinetant is a neurokinin-3 receptor antagonist. It works in the hypothalamus — the brain’s thermostat — by blocking neurokinin B, a signal that is overproduced when estrogen drops. Clinical trials show roughly a 60% reduction in moderate-to-severe hot flash frequency at twelve weeks. A 2025 safety and efficacy profile published in Expert Review of Clinical Pharmacology confirmed the benefit persists with long-term use and that liver enzyme monitoring (required every three months for the first year) catches the rare cases of transaminase elevation before they become dangerous (Taylor & Francis, 2025).

Elinzanetant (Bayer’s New Drug)

In October 2025, the FDA approved elinzanetant, another NK-3 receptor antagonist developed by Bayer. Phase 3 trial data presented at the 2025 Menopause Society meeting showed a 62% reduction in hot flash frequency at week 12, with improvements in sleep continuity and quality-of-life scores. Unlike fezolinetant, elinzanetant is dosed once daily at a fixed dose and does not require periodic liver monitoring. The arrival of two distinct NK-3 antagonists within three years fundamentally expands the non-hormonal treatment options. Before 2023, the only FDA-approved non-hormonal option for hot flashes was paroxetine (an SSRI), which delivered only a 30—40% reduction and came with sexual side effects. The NK-3 class is a genuine leap, not an incremental tweak.

Other Non-Hormonal Options

Gabapentin and pregabalin (anti-seizure drugs) reduce hot flash frequency by about 40—50% but cause dizziness and sedation. Clonidine (a blood pressure drug) is less effective and rarely used first-line. SSRIs/SNRIs (paroxetine, venlafaxine, desvenlafaxine) work for some women but have modest effect sizes. The evidence for gabapentin and SSRIs is from 2010s-era trials; the NK-3 drugs are clearly superior in both magnitude of effect and tolerability.

Trade-off: NK-3 antagonists cost more than generic SSRIs or gabapentin. Fezolinetant runs roughly $550/month without insurance. Insurance coverage is improving but not universal. For women who cannot tolerate hormones or have contraindications, the cost-benefit still favors the NK-3 drugs, but affordability remains a real barrier.

Natural and Lifestyle Interventions: What the Evidence Actually Says

The natural supplement industry is a multi-billion-dollar machine that runs on hope and weak data. Some interventions work. Most do not. Here is the breakdown.

Dietary Changes

A Mediterranean-style diet — heavy on vegetables, legumes, whole grains, fatty fish, and olive oil — consistently correlates with fewer hot flashes and better cardiovascular markers. A 2025 systematic review of dietary patterns and vasomotor symptoms found that higher adherence to Mediterranean and DASH diets reduced moderate-to-severe hot flash odds by 23% compared to standard Western diets. That is not a cure. It is a meaningful shift you can achieve without a prescription.

Phytoestrogens — plant compounds that weakly mimic estrogen — get outsized attention. Soy isoflavones have the best evidence, with some meta-analyses showing a 20—25% reduction in hot flash frequency when consumed at 40—80 mg daily. The effect is strongest in East Asian populations, possibly because gut microbiota in those populations more efficiently convert daidzein into equol (the active metabolite). Only about 30—40% of Western women harbor equol-producing bacteria. If you hate tofu, red clover extracts offer similar isoflavone profiles but with less consistent data. Flaxseed contains lignans, another phytoestrogen class, but the human trials are too small to draw firm conclusions.

Black Cohosh: The Most Studied Herb

Black cohosh (Actaea racemosa) is the most researched botanical for menopause. A 2024 meta-analysis of 12 randomized controlled trials found a modest but statistically significant reduction in hot flash frequency and severity compared to placebo, equivalent to roughly one fewer severe flash per day. The effect takes 4—8 weeks to appear. Crucially, liver toxicity concerns from early case reports were linked to products contaminated with a related Asian species, Actaea dahurica. Properly identified black cohosh has a clean safety profile in trials up to 12 months. The weird detail: black cohosh contains compounds called triterpene glycosides that bind to serotonin receptors — not estrogen receptors. It is not a phytoestrogen at all. The marketing copy calling it “natural estrogen” is factually wrong.

Other Supplements

Evening primrose oil: popular but worthless for hot flashes, with multiple negative trials. The gamma-linolenic acid content (the proposed active ingredient) is too low in standard doses to exert meaningful effects on thermoregulation.

Vitamin D and calcium: essential for bone health, yes. But supplementation only prevents fractures in women with documented deficiency. The U.S. Preventive Services Task Force recommends against daily calcium supplementation (800 mg or less) for fracture prevention in postmenopausal women, citing no net benefit and a small increase in kidney stones. Vitamin D of 600—800 IU/day is fine for general health, but mega-dosing does not improve menopausal symptoms.

Magnesium: weak evidence for sleep improvement, negligible data for hot flash reduction. Many women report subjective benefit, which may be real for them, but the trials do not support a general recommendation.

Exercise: Underdosed, Overlooked

Physical activity gets mentioned in every menopause guide as if it were a checkbox. It deserves better. Here is what the data actually show.

Regular aerobic exercise (brisk walking, cycling, swimming) done three to four times per week reduces hot flash frequency by roughly 10—20% over sixteen weeks. That is not the 75% reduction MHT delivers, but it is a 10—20% reduction with zero adverse effects, plus cardiovascular, metabolic, and mood benefits that no drug touches.

Resistance training twice per week preserves bone density. A 2024 trial from the Journal of Bone and Mineral Research found that postmenopausal women who performed supervised resistance training for twelve months lost only 0.5% spinal bone density compared to 2.8% in the control group — an 82% attenuation of bone loss. That is comparable to some bisphosphonate drugs, without the gastrointestinal side effects or the rare but serious risk of atypical femoral fracture.

High-intensity interval training (HIIT) improves cardiovascular fitness and insulin sensitivity but shows no advantage over steady-state exercise for hot flash reduction. Yoga and Pilates improve flexibility and reduce perceived stress but do not change hormone levels or bone density meaningfully.

The weird detail: a 2025 observational study of 4,800 women found that those who exercised outdoors had 15% fewer moderate-to-severe hot flashes than matched indoor exercisers, after controlling for temperature and duration. The hypothesized mechanism is circadian rhythm entrainment via morning light exposure, which stabilizes the body’s core temperature regulation set-point. The difference disappeared in women who exercised indoors before 8 a.m. or after 6 p.m.

Mind-Body Therapies: CBT and the Brain-Temperature Connection

Cognitive behavioral therapy (CBT) is not a treatment for hot flashes in the way MHT is. It does not reduce the frequency of flashes. What it does — and does well — is reduce the distress associated with them. A 2025 systematic review in BMC Women’s Health analyzed 14 randomized trials and found that CBT reduced hot flash-related bother and interference by moderate-to-large effect sizes, even though objective flash frequency remained unchanged (BMC Women’s Health, 2025). The practical implication: if you have three hot flashes per day but they no longer wake you at 3 a.m. or make you excuse yourself from meetings, that is a meaningful improvement.

CBT for menopause typically includes cognitive restructuring (challenging catastrophic thoughts about symptoms), paced breathing (slow, diaphragmatic breathing at six to eight breaths per minute during a flash), and sleep hygiene components. A short-term CBT protocol (six sessions over eight weeks) was shown in a 2025 Post Reproductive Health trial to improve quality-of-life scores by 18 points on the MENQOL scale, a clinically meaningful shift that persisted at six-month follow-up.

Hypnosis has a smaller evidence base but some striking individual trials. A single 2024 randomized trial of five sessions of clinical hypnosis reduced hot flash frequency by 68% at twelve weeks — a magnitude approaching MHT. The study was small (n = 78) and has not been independently replicated. The mechanism is believed to involve hypothalamic cooling instruction during trance, which directly modulates the thermoregulatory set-point. Replication trials are underway at three academic centers. If the result holds, hypnosis becomes a legitimate second-line option for women who cannot take hormones.

Trade-off: CBT requires a trained therapist, costs money (though many insurers cover it), and demands time and effort. Hypnosis is even harder to find. Neither is covered as a standalone menopause treatment by most health plans, though CBT for related conditions (anxiety, insomnia) often qualifies. Online self-guided CBT programs for menopause exist but have weaker evidence than face-to-face delivery.

Building Your Personal Treatment Plan

The right menopause treatment depends on four variables: your symptom profile, your medical history, your preferences, and your timing. Here is a framework for decision-making.

Step One: Categorize Your Symptoms

List every symptom you experience and rate severity (mild, moderate, severe). The most treatable symptoms with the strongest evidence base are vasomotor symptoms (hot flashes, night sweats) and genitourinary syndrome (vaginal dryness, pain with sex, urinary urgency). If those are your primary issues, MHT or an NK-3 antagonist should be on the table. If your main complaints are mood, sleep disruption without night sweats, or general fatigue, lifestyle interventions and CBT may take priority.

Step Two: Check for Contraindications

MHT is contraindicated in women with a personal history of breast cancer, unexplained vaginal bleeding, active liver disease, or a history of venous thromboembolism. Transdermal estrogen (patches, gels) carries lower clot risk than oral estrogen and may be an option even when oral is not, but guidelines still vary. If you have these contraindications, the NK-3 antagonists fezolinetant or elinzanetant become the first-line pharmacologic option for vasomotor symptoms.

Step Three: Layer Non-Pharmacologic Interventions

Exercise, diet, and CBT work additively with medication. A woman on MHT who also exercises and eats a Mediterranean diet will have better outcomes than one who takes MHT alone. A woman who cannot take any medication can still achieve meaningful symptom relief through exercise (10—20% flash reduction), dietary modification (15—25% reduction), layered CBT (reduced distress), and paced breathing during individual episodes. The sum is better than the parts.

Step Four: Reassess at Six and Twelve Months

Menopause is a transition, not a fixed state. Symptoms change. Bone density changes. Risk profiles change. A treatment that works at 48 may be inappropriate at 55. Annual review with your provider — preferably one who follows the 2025 ESE Clinical Practice Guideline (Endorsed by the Endocrine Society, EMAS, and the British Menopause Society) — keeps your plan current. The guideline recommends stratifying follow-up by symptom persistence, cardiovascular risk, and bone density trajectory.

The Bottom Line

The era of treating menopause as an embarrassing, barely-acknowledged condition is ending. 2025 was a watershed year — the FDA re-examined its own warnings, two new non-hormonal drugs reached the market, and major guidelines from the International Menopause Society and the European Society of Endocrinology aligned on the message that personalized, evidence-based menopause treatment should be available to every woman who needs it, not rationed by outdated fear.

If you are in perimenopause or early menopause and struggling, seek out a provider who offers the full spectrum — not one who reflexively prescribes hormones and not one who reflexively refuses them. The data support most women in the “window of opportunity.” The exceptions are real and deserve careful management, not blanket denial of care. You deserve a treatment plan that matches your body, not your doctor’s comfort zone.